|

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

RECRUITINGSponsored by Sonoma Biotherapeutics, Inc.
Actively Recruiting
SponsorSonoma Biotherapeutics, Inc.
Started2025-07-22
Est. completion2040-12
Eligibility
Age18 Years – 71 Years
Healthy vol.Accepted
Locations10 sites

Summary

To assess the emergence, type, severity, and potential causality of delayed adverse events following administration of a gene-modified Treg therapeutic.

Eligibility

Age: 18 Years – 71 YearsHealthy volunteers accepted
Inclusion Criteria:

* Subject was previously administered at least 1 dose of a Sonoma Biotherapeutics, Inc. gene-modified Treg therapeutic in a prior parent treatment protocol.
* Subject understands the purpose and risks of the study and is willing to provide written informed consent.
* Subject is willing to comply with all study procedures for the follow-up period.

Exclusion Criteria:

* Participation in the study is not in the subject's best interest, in the opinion of the Investigator

Conditions3

ArthritisHidradenitis Suppurativa (HS)Rheumatoid Arthritis (RA

Locations10 sites

UCSF Medical Center
Alex Carvidi628-206-2505alexcarvidi@ucsf.edu
Stanford Medical Center
Stanford, California, 94305
Uma Vilas Ayachit925-860-8966
University of Colorado
Aurora, Colorado, 80045
Jennifer Seifert303-724-7541jennifer.seifert@cuanschutz.edu
Northwestern University
John Seagrist312-503-0565john.seagrist@northwestern.edu
Tufts University
Andreas Klein617-636-5409tmncccr@tuftsmedicine.org

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.